Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | TYMS | P04818 | 5/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Fluorodeoxyuridylate SCHEMBL973436 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL6107 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL17117772 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15189164 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5491971 | 0.93 | LMNA (0.67) | LMNASMN1; SMN2TYMS | |
| SCHEMBL13026822 | 0.93 | LMNA (0.67) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15671694 | 0.92 | TYMS (0.64) | LMNASMN1; SMN2TYMS | |
| SCHEMBL28378385 | 0.92 | LMNA (0.66) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL25223991 | 0.91 | LMNA (0.69) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5491976 | 0.91 | LMNA (0.69) | LMNASMN1; SMN2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123190-A1 | 5'-POSITION DIBENZYL MONOPHOSPHATE DERIVATIVE OF NUCLEOSIDE-BASED ANTICANCER AGENT OR ANTIVIRUS AGENT | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123190-A1 | 5'-POSITION DIBENZYL MONOPHOSPHATE DERIVATIVE OF NUCLEOSIDE-BASED ANTICANCER AGENT OR ANTIVIRUS AGENT | DUT, DPYD, TYMP | LMNA 3010/4885SMN1; SMN2 2472/4885TYMS 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.